comparemela.com

Latest Breaking News On - Cintia piccina - Page 1 : comparemela.com

Adaptimmune Therapeutics : Transcript Q1 2024

Adaptimmune Q1 2024 Financial and Business Update Wednesday, May 15, 2024 - 8:00 AM ET C O R P O R A T E P A R T I C.

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q1 2024 Earnings Call Transcript

Operator: Good morning, ladies and gentlemen, and welcome to the Adaptimmune Q1 2024 Financial and Business Update Conference Call. I would now like to turn the meeting over to Ms. Juli Miller.

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 | The Kingston Whig Standard

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company s Sarcoma Franchise

Cintia Piccina returns as Chief Commercial Officer effective March 18, 2024 Philadelphia, Pennsylvania and Oxford, United Kingdom (Newsfile Corp. - February 27, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced the reappointment of Cintia Piccina as Chief Commercial Officer effective March 18, 2024. Cintia served in this role from January 2022 to March 2023. Cintia will lead a rapidly expanding comme

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.